As FIP is an immune complex disease (Addie et al., 2003; Berry, 2001), one can speculate that suppressing the expression of proteins such as IAP and TFF‐3 and stimulating the expression of proteins such as I‐FABP may affect disease progression. The gene discussed is ALPI; the disease is type III hypersensitivity disease.